Heart failure & cardiomyopathies
Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry
Authors' conclusion
Among women with PPCM, bromocriptine treatment in addition to standard of care was associated with better maternal outcomes after 6 months.
Study context
- Population
- Patients with peripartum cardiomyopathy in the EORP PPCM registry with available follow-up491 with primary endpoint
- Participants
- 552 patients
- Exposure
- Bromocriptine plus standard of care vs standard of care
- Bromocriptinen = 85
- Outcome
- Composite of:
- Death or hospital readmission within 6 months of diagnosis
- Persistent severe LV dysfunction (LVEF < 35%) at 6 months
- Follow-up
- 6 months
Methodological detailsexploratory non-randomised analysis of the EORP PPCM registry, inverse probability weighting, multiple imputation
- Exploratory non-randomised analysis of the EORP PPCM registry
- Inverse probability weighting
- Multiple imputation
Main finding
As reported in the abstract
Bromocriptine vs Standard of careOdds ratio (95% CI)P value
Complete case analysis
0.29(0.10–0.83)
P = 0.021Inverse probability weighted model on imputed data
0.47(0.31–0.70)
P < 0.001Observational data: associations, not effects.
Safety
Thromboembolic events
- Thromboembolic events: P = .900
Original publication
Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. Eur Heart J. Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →